An interventional study of Vitamin D and Placebo in Vitamin D Deficiency, Hepatocellular Carcinoma and Perioperative Complication, sponsored by National Taiwan University Hospital. Status unknown. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-12-14.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
The goal of this double-blind, randomized controlled trial is to test the effect of short-term and high-dose vitamin D therapy in patients undergoing hepatectomy for hepatocellular carcinoma.
Participants will receive short-term high dose of vitamin D during perioperative period.
The main questions the study aims to answer are:
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 200 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Vitamin D
Dietary Supplement: Placebo
576 000 IU D 5-7 days prior to the surgery and 144 000 IU daily on post-operative day 1-2
An equal volume of medium chain triglyceride (MCT, as placebo) to vitamin D 5-7 days prior to the surgery and on the post-operative day 1-2.
Infection rate
Diagnosed by clinical presentation and relevant biomarker
Time frame: Perioperative period
No study locations are listed for this record.
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital